Last reviewed · How we verify
NCT06362720: CMV
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
trial in CMV Infection or Reactivation After Allogenic HSCT in 158 participants. Not yet recruiting.
31 October 2024
Quick facts
| Lead sponsor | Siriraj Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 158 |
| Start date | 1 May 2024 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 December 2024 |
Conditions studied
- CMV Infection or Reactivation After Allogenic HSCT — all drugs for CMV Infection or Reactivation After Allogenic HSCT →
Sponsor
Siriraj Hospital
Who can join
15 and older, any sex, with CMV Infection or Reactivation After Allogenic HSCT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen. The main questions it aims to answer are: * How do CMV infection and reactivation differ between Allo-SCT patients who received a standard regimen versus those who received a Post-transplant Cyclophosphamide-based regimen? * progression-free survival, Median overall survival, cumulative incidence of relapse, non-relapsed mortality (NRM) and GvHD at 2 years after Allo-SCT * The impact of CMV infection and CMV reactivation on progression-free survival, overall survival, and NRM * Averse events of GVHD prophylaxis medication Participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06362720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Siriraj Hospital trials
Trials by the same sponsor.
- NCT07262034 — The Impact of Preoperative Nutrition Intervention on Muscle Mass Preserve in Older Adults Undergoing Elective Surgery · not yet recruiting
- NCT07402486 — A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer · Phase 2 · not yet recruiting
- NCT07298577 — Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ult · NA · not yet recruiting
- NCT07239908 — Resuscitation Enhancement to Avoid Rearrest Through Evidence-based Strategies in Prehospital Post-resuscitation Care · Phase 2, PHASE3 · not yet recruiting
- NCT07110961 — The Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Diagnosis of Restless Legs Syndro · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06362720 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Siriraj Hospital
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing